Clinical Trial Update: Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for Lorvotuzumab Mertansine in several relapsed/refractory pediatric solid tumors; study completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Peripheral Nerve Sheath Tumor
• Neuroblastoma
• Pleuropulmonary Blastoma
• Rhabdomyosarcoma
• Synovial Sarcoma
• Wilms Tumor

Drugs mentioned

• Lorvotuzumab Mertansine (lorvotuzumab mertansine)

Snippet

Sponsor: Children's Oncology Group | Conditions: Pleuropulmonary Blastoma, Recurrent Malignant Peripheral Nerve Sheath Tumor | Phase 2 | Status: COMPLETED | Results posted: 2019-08-29